Form 4: Biogen Director Stephen Sherwin Receives Stock Grant

Biogen Inc. director Stephen A. Sherwin was granted 1,505 restricted stock units as part of his compensation.

Summary

• Director Stephen A. Sherwin acquired 1,505 shares of Biogen Inc. (BIIB) common stock.
• The transaction occurred on June 9, 2026.
• The shares were acquired at a price of $0, representing a grant of restricted stock units (RSUs).
• Following this transaction, the director's total beneficial ownership is 15,193 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The restricted stock units vest on the earlier of the next annual meeting or the first anniversary of the grant date (June 9, 2027).

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units is consistent with standard compensation packages for board members at large-cap pharmaceutical companies like Amgen, Gilead, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 1,505 restricted stock units on the earlier of the next annual meeting or June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Form 4, Insider Trading, Director Compensation, Equity Grant